Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio remains on track to submit an NDA for seralutinib in PAH in September 2026 following a productive Pre-NDA Type B meeting with the FDA, where the agency characterized statistical significance issues as review rather than filing issues. The company reacquired worldwide rights to seralutinib from Chiesi, dissolving the prior U.S. profit share and returning ex-U.S. rights to Gossamer in exchange for a capped royalty and milestone payments.
Key figures
- Eps
- 0.05
- Revenue
- 9238000
- Ga expenses
- 8900000
- Rd expenses
- 26412000
- Cash position
- 57026000
- Chiesi payment
- 5000000
- Debt reduction principal
- 115900000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.